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ABSTRACT
Background: Filaggrin proteins are located in the skin
and prevent epidermal water loss and impede the entry
of micro-organisms, allergens and chemicals. Filaggrin
null mutations are strongly associated with ichthyosis
vulgaris and atopic dermatitis.
Objective: The authors aimed to investigate the
association between ﬁlaggrin null mutations, atopic
dermatitis and diabetes.
Design: A random sample of 3335 adults from the
general population in Denmark was ﬁlaggrin-
genotyped for R501X and 2282del4 null-mutations and
questioned about atopic dermatitis and diabetes.
Furthermore, two independent study populations of
patients with type 1 (n¼104) or 2 (n¼774) diabetes
were genotyped.
Results: In a crude data analysis, a positive
association was detected between the ﬁlaggrin null
genotype and, respectively, subjects from the general
population who reported diabetes (p¼0.04) and
patients with established type 2 diabetes (p¼0.073).
Adjustment for age and gender resulted in signiﬁcant
associations for patients with type 2 diabetes
(p¼0.048) and subjects with self-reported diabetes
(p¼0.032).
Conclusions: Adult Danes with a ﬁlaggrin null
genotype had a signiﬁcantly increased prevalence of
self-reported diabetes. This ﬁnding was replicated
when an independent sample of Danish patients with
established type 2 diabetes was compared with control
subjects from the general population.
INTRODUCTION
The outermost part of the skin acts as
a barrier that protects against damage
following exposure to, for example, mechan-
ical insults, UV light, extreme temperatures,
chemicals and micro-organisms. Further-
more, the skin has neuroendocrine and
immune functions. Filaggrin proteins are
crucial components of the terminal differen-
tiation of the epidermis by aggregating
keratin ﬁlaments. As such, ﬁlaggrin prevents
epidermal water loss and impedes the entry of
micro-organisms, allergens and chemicals.
1
The ﬁlaggrin null genotype is observed in
8e10% of the general population.
23Loss of
ﬁlaggrin expression disrupts the skin barrier
and is strongly associated with ichthyosis
vulgaris
4 and atopic dermatitis.
2 Further-
more, ﬁlaggrin null mutations are associated
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ARTICLE SUMMARY
Article focus
- A few studies have suggested the existence of an
inverse association between atopic dermatitis
and type 1 diabetes.
- The existence of a speciﬁc endotype of asthma
that is not driven by sensitisation but rather
driven by skin barrier dysfunction was recently
suggested.
- It is unknown whether a putative impairment of
the skin barrier may increase the propensity to
low-grade inﬂammation in other organs as well.
Key messages
- Data from a general population study suggested
that the prevalence of ﬁlaggrin null mutations
was higher in adult Danes who reported diabetes
than in non-diabetics.
- This ﬁnding was replicated when an independent
sample of Danish patients with type 2 diabetes
was compared with participants from the general
population who did not report diabetes and who
had normal fasting plasma-glucose and glycated
haemoglobin (HbA1c) levels.
Strengths and limitations of this study
- Two independent samples were investigated and
showed similar results.
- The question on self-reported diabetes was not
validated in the general population allowing for
misclassiﬁcation.
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Open Access Researchwith asthma and allergic rhinitis in combination with
atopic dermatitis.
56
Few studies have investigated the skin barrier function
in diabetics. An impaired state of stratum corneum
hydration and a decreased skin surface lipid content in
diabetic skin have been suggested in a mixed population
of type 1 and 2 diabetics, and in diabetic mice.
7 8 A
caseecontrol study found no difference in stratum
corneum hydration and transepidermal water loss
between diabetics and controls.
9 A few studies have
suggested the existence of an inverse association
between atopic dermatitis and type 1 diabetes; a ﬁnding
that may be explained by the T-helper (Th) cell 1 and 2
dichotomy.
10 11 To our knowledge, no studies so far have
investigated the possible association between diabetes
type 2 and atopic dermatitis.
Filaggrin genotyping was recently performed in 3335
adults from the general population in Copenhagen.
3 In
our data analyses, we noticed a relatively high frequency
of the null genotype in subjects who reported diabetes.
We therefore hypothesised that a putative impairment of
the skin barrier increases the propensity to low-grade
inﬂammation, which again, in concert with other factors,
could increase the risk of diabetes. In favour of such
a mechanism, Bønnelykke et al recently found a ﬁlaggrin-
associated pattern of atopic diseases in early childhood
characterised by early onset of atopic dermatitis, early
onset of asthma (independent of atopic dermatitis
status) with severe exacerbations and later development
of sensitisation.
12 Thus, the existence of a speciﬁc
endotype of asthma that is driven not by sensitisation but
rather by skin-barrier dysfunction was suggested, since
ﬁlaggrin is not expressed in airway mucosa.
Here, we investigated whether an association could be
found between self-reported diabetes and, respectively,
atopic dermatitis and ﬁlaggrin null mutation status. We
included two independent study populations of patients
who had type 1 or 2 diabetes, to determine whether
a possible association could be replicated.
MATERIALS AND METHODS
Study populations
Ethic statement
The Ethical Committee of Copenhagen County
approved the study (KA-20060011). Written and verbal
consent was given by the participants to be included in
the study and for their information to be stored in the
hospital database and used for research.
Three independent Danish populations were included
in the current study: (1) a random sample of adults from
the general population in Copenhagen
13; (2) patients
with type 1 diabetes
14; and (3) patients with type 2
diabetes.
Adults from the general population
Between June 2006 and May 2008, a cross-sectional study
was performed in the general population in Copen-
hagen. A random sample of 7931 subjects aged
18e69 years was obtained from the Danish Central
Personal Register. All were adults with Danish citizenship
and born in Denmark. A total of 3471 (43.7%) subjects
participated in a general health examination, and 3335
(96.1%) were ﬁlaggrin-genotyped for the 2282del4 and
R501X mutations. The participation rate was higher
among older age groups.
15
Patients with type 1 diabetes
A total of 104 patients diagnosed as having type 1
diabetes between 1981 and 2004 were randomly selected
from a large incident cohort.
14 All patients were diag-
nosed before age 18 years and according to WHO
criteria. They were all positive for protein tyrosine
phosphatase-like protein and/or glutamic acid decar-
boxylase 65 antibodies at diagnosis (0e3 months prior to
the ﬁrst insulin injection).
Patients with type 2 diabetes
Atotal of 774(299women,475 men; age65.2611.4 years;
BMI, 30.665.8 kg/m
2) unrelated patients diagnosed as
having type 2 diabetes sampled randomly from the
outpatient clinic at Steno Diabetes Center from 2005 to
2007 were included in the study.
Measurements (general population only)
Height and weight were measured in light indoor
clothing and without shoes. Waist circumference was
measured in the upright position midway between the
iliac crest and the lower costal margin. Body mass index
(BMI) was calculated in kg/m
2. Blood-pressure
measurements were performed after 5 min rest in the
sitting position with a mercury sphygmomanometer. If
the systolic or diastolic blood pressure exceeded 140 and
90 mm Hg, respectively, repeated measurements were
made later during the health examination with the
participant in a lying position. The lowest value was used.
Blood samples were drawn after a 12 h overnight fast.
Fasting plasma glucose was analysed by a glucose oxidase
method (Hitachi 912 system, Roche Diagnostics,
Mannheim, Germany). Glacated hemaglobin (HbA1c)
was analysed by the HPLC method (TOSOH, Minato,
Japan). Serum insulin was measured using the Auto-
DELFIA insulin kit (Perkin-Elmer/Wallac, Turku,
Finland). Fasting concentrations of total-, HDL- and
LDL cholesterol as well as triglyceride were measured
using enzymatic colorimetric methods (Roche Molecular
Biochemicals, Mannheim, Germany).
16 The homeostasis
model assessment of insulin resistance (HOMA-IR) was
used to estimate the degree of insulin resistance. The
HOMA-IR index was estimated from fasting plasma
glucose and fasting serum insulin concentrations using
the following formula: HOMA-IR index¼(fasting plasma
glucose (mmol/l)$fasting serum insulin (mU/l))/22.5.
17
Filaggrin genotyping
Regions covering the mutations R501X and 2282del4 of
the ﬁlaggrin gene were ampliﬁed from genomic DNA by
PCR, and the obtained DNA fragments were hybridised
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Filaggrin and diabetesto both mutation-speciﬁc and wildtype-speciﬁc probes
attached to ﬂuorescent micro beads (Luminex, Austin,
Texas), and subsequently analysed on a BioPlex 200
(Biorad, Hercules, California).
3
Questionnaire (general population only)
Participants from the cross-sectional general population
study were sent a standard invitation letter and a ques-
tionnaire on health, lifestyle and socio-economic factors.
One question addressed diabetes. An afﬁrmative answer
to the question ‘Have you ever been told that you
suffered from diabetes?’ was used to identify subjects
with diabetes. Thus, no questions were used that
potentially could differentiate between subjects with type
1 and 2 diabetes.
A history of atopic dermatitis was deﬁned by the UK
Working Party’s diagnostic criteria for atopic dermatitis
as a history of an itchy skin condition plus a minimum
of two of four minor criteria.
18 The minor criteria were:
(1) a history of involvement of the skin creases, (2)
a personal history of asthma or hay fever, (3) a history of
general dry skin in the last year and (4) onset before the
age of 2 years.
Statistical analysis
Deviation from the HardyeWeinberg equilibrium
was tested using the free online calculator at the
Online Encyclopedia for Genetic Epidemiology studies
(http://www.oege.org/software/hwe-mr-calc.shtml) for
bothﬁlaggrinnull mutations.Theﬁlaggrinnull genotype
was deﬁned as subjects who were either heterozygotic or
homozygotic for mutations R501X or 2282del4.
Based on data from the general population study,
three subgroups were constructed: a ‘non-diabetes
group’ (n¼3136), a ‘screen-detected diabetes group’
(n¼66) and a ‘self-reported diabetes group’ (n¼133).
Non-diabetics gave a negative answer to the question
about diabetes and had a fasting glucose of <7 mmol/l
and HbA1c of <6.5%. Screen-detected diabetics did not
report diabetes but had a fasting glucose $7 mmol/l
(n¼58) and/or HbA1c $6.5% (n¼8). Finally, diabetics
reported diabetes in the questionnaire. Two additional
subgroups were constructed based on the two indepen-
dent study populations of patients with diabetes, the type
1 diabetes group (n¼104) and the type 2 diabetes group
(n¼774) (table 1).
Logistic regression analyses using data from the general
population study and from the cohorts of patients with type 1
and/or 2 diabetes (table 2)
A logistic regression model was performed with ‘ﬁlaggrin
null mutation status’ as the dependent variable, and with
gender, age and diabetes subgroup (‘non-diabetes,’
‘screen-detected diabetes,’ ‘self-reported diabetes,’ ‘type
1 diabetes’ and ‘type 2 diabetes’) as the independent
variables. In this model, a test for interaction between
age and ﬁlaggrin mutation status was performed using
a log-likelihood ratio test. This was done to test whether
an association between ﬁlaggrin mutation status and
diabetes status could depend on age. Another logistic
regression analysis was performed with ‘diabetes’ as the
dependent variable (‘self-reported diabetics’ and
‘screen-detected diabetics’ from the general population
as well as patients from the ‘type 2 diabetes group’ were
registered as diabetics, whereas patients with type 1
diabetes were regarded as missing data) and ﬁlaggrin
mutation status (‘wildtype,’ ‘null-mutation’) and BMI
(‘<25,’ ‘25e30,’ ‘>30’ kg/m
2) as the independent vari-
ables. In this analysis, an interaction term between
ﬁlaggrin mutation status and BMI was inserted to
determine whether the association between ﬁlaggrin
mutations and diabetes depended signiﬁcantly on BMI.
Logistic regression analysis using data from the general
population only (table 3)
‘Self-reported atopic dermatitis’ was used as the inde-
pendent variable, and gender, age, diabetes subgroup
(‘non-diabetes,’ ‘screen-detected diabetes’ and ‘self-
reported diabetes’) and ﬁlaggrin mutation status
(‘wildtype,’ ‘null-mutation’) were explanatory variables.
In a similar regression analysis, a test for interaction
between diabetes subgroup and ﬁlaggrin mutation status
was performed using a log-likelihood ratio test. This was
carried out to determine whether the association
between atopic dermatitis and diabetes depended
signiﬁcantly on ﬁlaggrin mutation status.
Characteristics were compared using the c
2 test. One-
way ANOVA was used to compare means between
different subgroups. Associations were expressed as ORs
with 95% CIs. Data analyses were performed using SPSS
for Windows (release 15.0).
RESULTS
A total of 3335 participants from the general population
study (55.3% women), 104 patients diagnosed as having
type 1 diabetes (40.4% women) and 774 patients diag-
nosed as having type 2 diabetes (38.5% women) were
genotyped for the R501X and 2282del4 ﬁlaggrin null
mutations. The observed genotype prevalences of both
polymorphisms did not deviate signiﬁcantly (p>0.05)
from the expected prevalences under the HardyeWein-
berg equilibrium assumption in any of these three
populations.
The prevalence of self-reported diabetes was 4% in the
general population (3.3% in women and 4.9% in men)
(table 1). The vast majority of participants who reported
diabetes were expected to suffer from type 2 diabetes. To
add evidence to this assumption, we calculated the
HOMA-IR in subjects without diabetes, those with
screen-detected diabetes and those with self-reported
diabetes (table 1). One-way ANOVA analysis revealed
a statistically signiﬁcant difference in the HOMA-IR
mean between the three subgroups (p<0.001). This
supports the notion that type 2 diabetes was likely for the
majority of cases with self-reported diabetes.
The prevalence of ﬁlaggrin mutations and atopic
dermatitis was, respectively, 7.8% (95% CI 7.0 to 8.8) and
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Filaggrin and diabetes9.9% (95% CI 8.8 to 10.9) in non-diabetics, 9.1% (95%
CI 3.9 to 18.8) and 9.1% (95% CI 2.1 to 16.1) in screen-
detected diabetics, 12.8% (95% CI 8.0 to 19.6) and
13.5% (95% CI 7.6 to 19.3) in self-reported diabetics,
6.7% (95% CI 3.1 to 13.5) in patients with type 1 dia-
betes and 9.8% (95% CI 7.9 to 12.1) in patients with
established type 2 diabetes. In a crude data analysis, no
signiﬁcant difference could be identiﬁed between non-
diabetic participants from the general population and,
respectively, participants from the general population
with screen-detected diabetes (p¼0.71) or patients with
type 1 diabetes (p¼0.67). However, in patients with type
2 diabetes (p¼0.073), an almost signiﬁcant association
was detected, and in participants from the general
population with self-reported diabetes, a signiﬁcant
association was identiﬁed (p¼0.04). Some 41.7% had
a BMI below 25 kg/m
2 (men¼32.5%, women¼50.6%),
35.8% had a BMI between 25 and 30 kg/m
2
(men¼43.8%, women¼28.8%), whereas 22% had a BMI
above 30 kg/m
2 (men¼23.8%, women¼20.7%).
A logistic regression model was performed with ‘ﬁlag-
grin null mutation status’ as the dependent variable and
revealed no signiﬁcant interaction term (p¼0.33)
between age and diabetes. This means that stratiﬁcation
by age group was not necessary. However, the analysis
revealed a positive and signiﬁcant association between
ﬁlaggrin null mutation status and, respectively, ‘self-
reported diabetes’ and ‘type 2 diabetes,’ when compared
with non-diabetic controls from the general population.
Another logistic regression analysis was performed with
‘diabetes’ as the dependent variable and revealed a posi-
tive and signiﬁcant association with ﬁlaggrin null geno-
type (table 2). An interaction term between ﬁlaggrin
mutation status and BMI was signiﬁcant (p¼0.03); hence,
ﬁlaggrin mutations were positively associated with
diabetes in subjects with low BMI. Thus, when separate
regression analyses were made with diabetes as the
dependentvariableandsex,ageandﬁlaggrinmutationas
the explanatory variables in subjects with BMI<25,
BMI¼25e30 and BMI>30 kg/m
2, the OR for ﬁlaggrin
mutationwas,respectively,2.08(95%CI1.15to3.76),1.51
(95% CI 0.91 to 2.48) and 1.11 (95% CI 0.66 to 1.88).
Finally, a logistic regression analysis restricted to the
general population data was performed with ‘atopic
dermatitis’ as the independent variable and revealed
a positive and signiﬁcant association between atopic
Table 2 Two logistic regression analyses with the outcome ﬁlaggrin null mutation status and diabetes, respectively, and
adjusted for variables shown in the table as well as age
Explanatory variables
General population, patients with type 1 and 2 diabetes (n[4213)
Filaggrin null mutation
Percentage (n/ntotal) Adjusted OR* with 95% CI
Sex
Men 7.8 (159/2029) 1 (reference)
Women 8.8 (193/2184) 1.18 (0.94 to 1.47)
Group
Non-diabetic 7.8 (246/3136) 1 (reference)
Screen-detected diabetes 9.1 (6/66) 1.23 (0.52 to 2.88)
Self-reported diabetes 12.8 (17/133) 1.78 (1.05 to 3.04)z,p ¼0.032
Type 1 diabetes 6.7 (7/104) 0.86 (0.39 to 1.87)
Type 2 diabetes 9.8 (76/774) 1.37 (1.003 to 1.89)z,p ¼0.048
General population and patients with type 2 diabetes (n[4109)
Explanatory variables
Diabetesy
Percentage (n/ntotal) Adjusted OR* with 95% CI
Sex
Men 29.8 (586/1967) 1 (reference)
Women 18.1 (387/2142) 0.56 (0.46 to 0.67)z,p ¼0.001
Filaggrin
Wild type 23.2 (874/3764) 1 (reference)
Null mutation 28.2 (99/345) 1.50 (1.10 to 2.06)z,p ¼0.011
BMI (kg/m
2)
<25 9.7 (167/1713) 1 (reference)
25e30 23.2 (341/1469) 1.97 (1.56 to 2.47)z,p ¼0.001
>30 49.1 (461/905) 7.36 (5.79 to 9.36)z,p ¼0.001
Non-diabetic, healthy controls from the general population in Copenhagen; Screen-detected diabetes, diabetes screening group deﬁned as
subjects who did not report diabetes but who had a fasting blood glucose $7 and/or glycated haemoglobin $6.5%. Self-reported diabetes,
diabetes group deﬁned as subjects who gave an afﬁrmative answer to the question: ‘Have you ever been told that you suffered from diabetes?’
*Mutually adjusted for variables shown in the table and age.
yDiabetes was deﬁned as belonging to the ‘screen-detected diabetes group,’ the ‘self-reported diabetes group,’ or the ‘type 2 diabetes group.’
The ‘type 1 diabetes groups’ was regarded as missing data.
zStatistically signiﬁcant.
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Filaggrin and diabetesdermatitis and self-reported diabetes (table 3). A test for
interaction between diabetes subgroup and ﬁlaggrin
mutation status was negative (p¼0.88). Thus, the
increased risk of diabetes in participants with atopic
dermatitis did not depend on ﬁlaggrin mutation status.
DISCUSSION
Data from the general population study suggested that
the prevalence of ﬁlaggrin null mutations and atopic
dermatitis was higher in adult Danes who reported
diabetes than in non-diabetics (tables 1e3). This ﬁnding
was replicated when an independent sample of Danish
patients with type 2 diabetes was ﬁlaggrin-genotyped and
compared with participants from the general population
who did not report diabetes and who had normal fasting
plasma-glucose and HbA1c levels (table 2). No infor-
mation about atopic dermatitis status was available from
the sample of type 1 and 2 diabetes patients. For this
reason, we could not determine whether ﬁlaggrin
mutation status worked as a proxy for atopic dermatitis
owing to the strong positive association between atopic
dermatitis and ﬁlaggrin null mutation status or whether
an association could be attributed to the ﬁlaggrin null
genotype only. However, we showed that ﬁlaggrin null
mutations did not increase the risk of diabetes in
subjects with atopic dermatitis. We found a borderline
signiﬁcant interaction between ﬁlaggrin mutations and
BMI in a logistic regression analysis with diabetes as the
dependent variable. This ﬁnding suggests that if ﬁlag-
grin mutations truly increase the risk of developing
diabetes, this might mainly be a factor in subjects with
a low BMI. Thus, in obese subjects, factors other than the
ﬁlaggrin genotype are of greater importance.
The vast majority of participants who reported
diabetes were suspected of suffering from type 2 diabetes
rather than the less prevalent type 1 diabetes. In support
of this notion, a higher HOMA-IR was identiﬁed in
participants who reported diabetes (table 1). A data
analysis revealed that the prevalence of ﬁlaggrin null
mutations was lower in patients with type 1 diabetes. This
came as no surprise, since previous studies have identi-
ﬁed an inverse association between type 1 diabetes and
atopic dermatitis explained by the Th1/Th2 dichotomy.
Thus, a Danish caseecontrol study showed that among
children who developed type 1 diabetes, the incidence of
atopic dermatitis was signiﬁcantly lower than in the
controls before the onset of type 1 diabetes (OR¼0.49;
95% CI 0.39 to 0.63).
10 A large German caseecontrol
study showed that atopic dermatitis was less frequent in
diabetic (13.3%) than in non-diabetic children (18.0%)
and that atopic dermatitis was signiﬁcantly associated
with a reduced risk of type 1 diabetes (adjusted
OR¼0.71; 95% CI 0.53 to 0.96).
11
There were weaknesses in this study that should be
addressed. First, genotyping was only performed for
R501X and 2282del4, which cover approximately 85% of
null mutations in the ﬁlaggrin gene among Caucasians.
19
Second, the occurrence of atopic dermatitis was based on
the UK Working Party’s Criteria, which have a sensitivity
and speciﬁcity of 92% and 81%, respectively.
18 Third, the
question used to identify subjects with diabetes in
the general population study has never been validated.
Although this may have contributed additionally
to misclassiﬁcation in this study, table 1 shows that vari-
ables differed markedly between participants with and
without self-reported diabetes. Missing information about
serum C-peptid concentrations, insulin therapy and onset
of diabetes might have been a better way to establish
a diabetes diagnosis. Fourth, owing to small study popu-
lations, random error may have affected the study
outcome. Thus, since this is the ﬁrst study on this topic, we
cannot exclude the possibility that the observed associa-
tions could be a type 1 error. Fifth, selection bias may have
inﬂuenced the positive association between self-reported
atopic dermatitis and type 2 diabetes, as patients who visit
their physician because of a chronic disorder are more
Table 3 Logistic regression analyses with the outcome diabetes status and adjusted for variables shown in the table as well as
age
Explanatory variables
General population only (n[3335)
Atopic dermatitis
18
Crude OR with 95% CI Adjusted OR* with 95% CI
Sex
Men 1 (reference) 1 (reference)
Women 2.27 (1.79 to 2.95)y,p <0.001 2.25 (1.74 to 2.89)y,p <0.001
Filaggrin
Wild type 1 (reference) 1 (reference)
Null mutation 2.71 (1.92 to 3.71)y,p <0.001 2.65 (1.92 to 3.67)y,p <0.001
Group
Non-diabetic 1 (reference) 1 (reference)
Screen-detected diabetes 0.91 (0.39 to 2.12) 1.22 (0.51 to 2.89)
Self-reported diabetes 1.42 (0.85 to 2.37) 1.72 (1.01 to 2.93)y,p ¼0.045
Non-diabetic: healthy controls from the general population in Copenhagen; Screen-detected diabetes: diabetes screening group deﬁned as
subjects who did not report diabetes but who had a fasting blood glucose $7 and/or glycated haemoglobin $6.5%; Self-reported diabetes:
diabetes group deﬁned as subjects who gave an afﬁrmative answer to the question: ‘Have you ever been told that you suffered from diabetes?’
*Mutually adjusted for variables shown in the table and age.
yStatistically signiﬁcant.
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Filaggrin and diabeteslikely to undergo evaluation for other disorders. However,
since patients with type 1 diabetes had a lower prevalence
of ﬁlaggrin null mutations, and since such patients also
regularly visit their physician, this may explain the positive
association only to a small degree. Since the onset of
atopic dermatitis occurs primarily in early childhood, and
type 2 diabetes typically begins in adulthood, atopic
dermatitis is likely to precede diabetes. Despite the
presented weaknesses, general population studies are
generally less biased than studies including patients and
may be used to generate new hypotheses.
Thisstudyhadaverynovelﬁndingandraisesimportant
questions, that is, is the increasing prevalence of type 2
diabetesandatopicdermatitisrelated?Couldourﬁndings
beexplainedbyanincreasedriskofdiabetesfollowingthe
use of topical corticosteroids in individuals with
a disrupted skin barrier, despite such medicaments
generally penetrating to a very small degree? Could
repeated short-term oral corticosteroid therapy in some
individuals with moderate to severe atopic dermatitis
increase the risk of type 2 diabetes? Could chemicals,
proteins and haptens that penetrate ﬁlaggrin-deﬁcient
skin more easily than normal skin in fact increase the
propensity to develop low-grade inﬂammation, which
again,inconcertwithotherfactors,couldincreasetherisk
of type 2 diabetes? These clinical questions are deﬁnitely
importanttoexplorefurther,sincetheymayinﬂuencethe
diagnostic work-up and clinical course for patients with
atopic dermatitis. Hence, further studies are obviously
warranted to conﬁrm or falsify our results, preferably
prospective ones. A recent study is indirectly in favour
of an association between atopic dermatitis and type 2
diabetes.
20 In children with term births, maternal gesta-
tional diabetes was signiﬁcantly associated with atopic
dermatitis (OR¼7.2; 95% CI 1.5 to 34.5) and allergen
sensitisation(OR¼5.7;95%CI1.2to28.0)intheoffspring.
If an association between atopic dermatitis/ﬁlaggrin null
genotype and type 2 diabetes can be replicated in other
studies, it might be considered to screen patients with
atopic dermatitis for diabetes to a higher degree or limit
theuseoforalcorticosteroidtherapy.Sincewebelievethis
area should be explored further, we plan to reinvestigate
the association between the ﬁlaggrin null mutations and
diabetes in a 30-year follow-up study from the general
population in Copenhagen and conduct cross-linkage
studies of diabetes and atopic dermatitis databases.
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